Survival of Patients with Prostate Cancer in Yazd, Iran |
Zahir, Shokouh Taghipour
(Department of Pathology, Shahid Sadoughi Hospital)
Nazemian, Mohammad Reza (School of Medicine, Shahid Sadoughi University of Medical Sciences) Zand, Sanaz (School of Medicine, Shahid Sadoughi University of Medical Sciences) Zare, Samad (Department of Urology, Shahid Sadoughi University of Medical Sciences) |
1 | Theoret MR, Ning YM, Zhang JJ, et al (2011). The risks and benefits of 5alpha-reductase inhibitors for prostate-cancer prevention. N Engl J Med, 365, 97-9. DOI ScienceOn |
2 | Andren O, Fall K, Franzen L, et al (2006). How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. J Urol, 175, 1337-40. DOI ScienceOn |
3 | Bostwick DG, Burke HB, Djakiew D, et al (2004). Human prostate cancer risk factors. Cancer, 101, 2371-490. DOI ScienceOn |
4 | Bouchardy C, Mirra AP, Khlat M, et al (1991). Ethnicity and cancer risk in Sao Paulo, Brazil. Cancer Epidemiol Biomarkers Prev, 1, 21-7. |
5 | Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30. DOI ScienceOn |
6 | Stark JR, Perner S, Stampfer MJ, et al (2009). Gleason score and lethal prostate cancer: does 3+4=4+3? J Clin Oncol, 27, 3459-64. DOI ScienceOn |
7 | Thompson IM, Jr., Goodman PJ, Tangen CM, et al (2013). Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med, 369, 603-10. DOI ScienceOn |
8 | Watanabe M, Nakayama T, Shiraishi T, et al (2000). Comparative studies of prostate cancer in Japan versus the United States. A review. Urol Oncol, 5, 274-83. DOI ScienceOn |
9 | Zlotta AR, Egawa S, Pushkar D, et al (2013). Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst, 105, 1050-8. DOI ScienceOn |
10 | Platz EA, Rimm EB, Willett WC, et al (2000). Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst, 92, 2009-17. DOI ScienceOn |
11 | Makarov DV, Sanderson H, Partin AW, Epstein JI (2002). Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4+3 and 3+4 independent of the number of involved cores? J Urol, 167, 2440-2. DOI ScienceOn |
12 | Mohagheghi MA, Mosavi-Jarrahi A, Malekzadeh R, Parkin M (2009). Cancer incidence in Tehran metropolis: the first report from the Tehran Population-based Cancer Registry, 1998-2001. Arch Iran Med, 12, 15-23. |
13 | Mousavi SM, Gouya MM, Ramazani R, et al (2009). Cancer incidence and mortality in Iran. Ann Oncol, 20, 556-63. |
14 | Quinn M, Babb P (2002). Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int, 90, 162-73. DOI ScienceOn |
15 | Rasiah KK, Stricker PD, Haynes AM, et al (2003). Prognostic significance of Gleason pattern in patients with Gleason score 7 prostate carcinoma. Cancer, 98, 2560-5. DOI ScienceOn |
16 | Sadjadi A, Nooraie M, Ghorbani A, et al (2007). The incidence of prostate cancer in Iran: results of a population-based cancer registry. Arch Iran Med, 10, 481-5. |
17 | Shibata A, Whittemore AS (1997). Genetic predisposition to prostate cancer: possible explanations for ethnic differences in risk. Prostate, 32, 65-72. DOI |
18 | Siegel R, DeSantis C, Virgo K, et al (2012a). Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin, 62, 220-41. DOI |
19 | Siegel R, Naishadham D, Jemal A (2012b). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29. DOI ScienceOn |
20 | Dunn JE (1975). Cancer epidemiology in populations of the United States--with emphasis on Hawaii and California--and Japan. Cancer Res, 35, 3240-5. |
21 | Chan TY, Partin AW, Walsh PC, Epstein JI (2000). Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urol, 56, 823-7. DOI ScienceOn |
22 | Crawford ED (2003). Epidemiology of prostate cancer. Urology, 62, 3-12. |
23 | Crawford ED (2009). Understanding the epidemiology, natural history, and key pathways involved in prostate cancer. Urology, 73, 4-10. DOI ScienceOn |
24 | Epstein JI (2010). An update of the Gleason grading system. J Urol, 183, 433-40. DOI ScienceOn |
25 | Holmberg L, Robinson D, Sandin F, et al (2012). A comparison of prostate cancer survival in England, Norway and Sweden: A population-based study. Cancer Epidemiol, 36, 7-12. DOI ScienceOn |
26 | Hsing AW, Tsao L, Devesa SS (2000). International trends and patterns of prostate cancer incidence and mortality. Int J Cancer, 85, 60-7. DOI |
27 | Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. DOI |
28 | Jemal A, Siegel R, Xu J, Ward E (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300. DOI |
29 | Jemal A, Thomas A, Murray T, Thun M (2002). Cancer statistics, 2002. CA Cancer J Clin, 52, 23-47. DOI ScienceOn |
30 | Kramer BS, Hagerty KL, Justman S, et al (2009). Use of 5-alphareductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol, 27, 1502-16. DOI ScienceOn |